Cosomil, Inc.
Tokyo, JP · 3 known investors
Cosomil develops single-molecule enzyme activity measurement technology for early disease diagnosis and drug development support in healthcare. The company serves medical research institutions, pharmaceutical manufacturers, and diagnostic laboratories in Japan.
Also known as Cosomil · コウソミル株式会社
Founders & leadership
Investors · 3
Company profile
researched Aug 2026Cosomil, Inc. (コウソミル株式会社) is a Tokyo-based healthcare technology company developing a "single-molecule enzyme activity-based liquid biopsy" platform. The company's stated approach is to measure and image the activity of a range of enzymes in blood at single-molecule level ultra-high sensitivity, using fluorescent enzyme substrates combined with microdevices, in order to build high-precision diagnostic methods.
The company applies this platform to two business lines: development of diagnostic agents for early detection of disease, and drug development support services. A specific stated focus is early detection of pancreatic cancer. Cosomil also runs a clinical feasibility study referred to as the Enzebar (エンゼバー) feasibility study, for which it has published an information website and reported enrollment of its first subject.
Business model
Cosomil operates two business lines: development of early-stage disease diagnostic agents and drug development support services built on its single-molecule enzyme activity measurement platform [0].
Traction
The company reported achieving First Subject In in its Enzebar feasibility study in March 2026 and publication of JST START-funded research results in the journal Cell Biomaterials in May 2026 [0].
Latest developments
Company news in 2026 included the March announcement of First Subject In (first patient enrollment) in the Enzebar feasibility study, publication in June of an information website for that study, and an August announcement of a site expansion to the University of Tokyo Entrepreneur Plaza with a corresponding head office address change. In May 2026, research results from work under the JST START program were published in the journal Cell Biomaterials [0].
▸Full profile — technology, go-to-market, geography
Technology
The core technology is single-molecule measurement and imaging of enzyme activity, described by the company as a "single-molecule measurement liquid biopsy." It combines fluorescent enzyme substrates with microdevices to evaluate the activity of various enzymes present in blood at single-molecule-level ultra-high sensitivity, which the company positions as the basis for high-precision diagnostic techniques [0].
Go-to-market
The company's drug development support and diagnostic development activities are oriented toward the healthcare and pharmaceutical research sector [0].
Geography
Operations are in Japan, with the head office located in Tokyo; in August 2026 the company announced expansion of its base to the University of Tokyo Entrepreneur Plaza together with a change of registered head office address [0].
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Timeline · 4
launches, deals, and filingsCosomil announced the expansion of its base to the University of Tokyo Entrepreneur Plaza and a change of its registered head office location.
The company launched a website providing information on the Enzebar feasibility study.
Research results produced under the JST START program were published in the journal Cell Biomaterials.
Cosomil announced enrollment of the first subject (First Subject In) in its Enzebar feasibility study.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 1
primary sources listed
- Cosomil, Inc.cosomil.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Cosomil, Inc. do?
- Japanese developer of single-molecule enzyme activity liquid biopsy technology for early disease diagnostics and drug development support.
- Who founded Cosomil, Inc.?
- Cosomil, Inc. was founded by 鏡味 優.
- Who are Cosomil, Inc.'s investors?
- Cosomil, Inc.'s investors include Coral Capital, Delight Ventures, ANRI.
- Where is Cosomil, Inc. headquartered?
- Cosomil, Inc. is headquartered in Tokyo, JP.